Business
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform today announced that Company management is scheduled to present at the Citizens (JMP) Life Sciences Conference in New York City on Thursday, May 8 at 11:30 AM EDT. A live webcast of the Company’s fireside chat will be available from the “I
About this update from Proqr Therapeutics N.v.
[{"type":"image","alt":"ProQR Therapeutics N.V.","displaySize":"","headline":null,"caption":"ProQR Therapeutics N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/044666b5bdc9e0d99686bfed8e7211d3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4HUbXKqR88bsVsQR5pPVmw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/044666b5bdc9e0d99686bfed8e7211d3","width":150,"height":150}},"lazy":false},{"type":"text","content":"LEIDEN, Netherlands & CAMBRIDGE, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform today announced that Company management is scheduled to present at the Citizens (JMP) Life Sciences Conference in New York City on Thursday, May 8 at 11:30 AM EDT.","length":428,"tagName":"p"},{"type":"text","content":"A live webcast of the Company’s fireside chat will be available from the “Investors & Media” section of ProQR’s website under “Events”. A replay of the webcast will then be available for approximately 30 days.","length":213,"tagName":"p"},{"type":"text","content":"About Axiomer™","length":14,"tagName":"p"},{"type":"text","content":"ProQR is pioneering a next-generation RNA base editing technology called Axiomer™, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer™ “Editing Oligonucleotides”, or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer™ EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease.","length":791,"tagName":"p"},{"type":"text","content":"About ProQR","length":11,"tagName":"p"},{"type":"text","content":"ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA ther...